BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 30825461)

  • 1. Increased Expression of Renal Drug Transporters in a Mouse Model of Familial Alzheimer's Disease.
    Pan Y; Omori K; Ali I; Tachikawa M; Terasaki T; Brouwer KLR; Nicolazzo JA
    J Pharm Sci; 2019 Jul; 108(7):2484-2489. PubMed ID: 30825461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Altered Expression of Small Intestinal Drug Transporters and Hepatic Metabolic Enzymes in a Mouse Model of Familial Alzheimer's Disease.
    Pan Y; Omori K; Ali I; Tachikawa M; Terasaki T; Brouwer KLR; Nicolazzo JA
    Mol Pharm; 2018 Sep; 15(9):4073-4083. PubMed ID: 30074800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intestinal Permeability and Oral Absorption of Selected Drugs Are Reduced in a Mouse Model of Familial Alzheimer's Disease.
    Jin L; Pan Y; Tran NLL; Polychronopoulos LN; Warrier A; Brouwer KLR; Nicolazzo JA
    Mol Pharm; 2020 May; 17(5):1527-1537. PubMed ID: 32212738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor.
    Yamada A; Maeda K; Kamiyama E; Sugiyama D; Kondo T; Shiroyanagi Y; Nakazawa H; Okano T; Adachi M; Schuetz JD; Adachi Y; Hu Z; Kusuhara H; Sugiyama Y
    Drug Metab Dispos; 2007 Dec; 35(12):2166-76. PubMed ID: 17823233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug-metabolizing enzyme and transporter expression in a mouse model of diabetes and obesity.
    Cheng Q; Aleksunes LM; Manautou JE; Cherrington NJ; Scheffer GL; Yamasaki H; Slitt AL
    Mol Pharm; 2008; 5(1):77-91. PubMed ID: 18189363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Region-specific blood-brain barrier transporter changes leads to increased sensitivity to amisulpride in Alzheimer's disease.
    Sekhar GN; Fleckney AL; Boyanova ST; Rupawala H; Lo R; Wang H; Farag DB; Rahman KM; Broadstock M; Reeves S; Thomas SA
    Fluids Barriers CNS; 2019 Dec; 16(1):38. PubMed ID: 31842924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Role of drug transporters in rational use of drugs 
at high altitude area].
    Li W; Yan B; Wang R; Jia Z
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2018 Mar; 43(3):327-332. PubMed ID: 29701197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal Drug Transporters and Drug Interactions.
    Ivanyuk A; Livio F; Biollaz J; Buclin T
    Clin Pharmacokinet; 2017 Aug; 56(8):825-892. PubMed ID: 28210973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The kidney--the body's playground for drugs: an overview of renal drug handling with selected clinical correlates.
    Perri D; Ito S; Rowsell V; Shear NH
    Can J Clin Pharmacol; 2003; 10(1):17-23. PubMed ID: 12687033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alterations in transporter expression in liver, kidney, and duodenum after targeted disruption of the transcription factor HNF1alpha.
    Maher JM; Slitt AL; Callaghan TN; Cheng X; Cheung C; Gonzalez FJ; Klaassen CD
    Biochem Pharmacol; 2006 Aug; 72(4):512-22. PubMed ID: 16806085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors.
    Uchida Y; Ohtsuki S; Katsukura Y; Ikeda C; Suzuki T; Kamiie J; Terasaki T
    J Neurochem; 2011 Apr; 117(2):333-45. PubMed ID: 21291474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disease-Induced Alterations in Brain Drug Transporters in Animal Models of Alzheimer's Disease : Theme: Drug Discovery, Development and Delivery in Alzheimer's Disease Guest Editor: Davide Brambilla.
    Vellonen KS; Ihalainen J; Boucau MC; Gosselet F; Picardat T; Gynther M; Kanninen KM; White AR; Malm T; Koistinaho J; Forsberg MM; Ruponen M
    Pharm Res; 2017 Dec; 34(12):2652-2662. PubMed ID: 28952054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of Amino Acid/Drug Transporters for Renal Transport of [
    Ono M; Baden A; Okudaira H; Kobayashi M; Kawai K; Oka S; Yoshimura H
    Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27754421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interindividual and Regional Variability in Drug Transporter Abundance at the Human Blood-Brain Barrier Measured by Quantitative Targeted Proteomics.
    Billington S; Salphati L; Hop CECA; Chu X; Evers R; Burdette D; Rowbottom C; Lai Y; Xiao G; Humphreys WG; Nguyen TB; Prasad B; Unadkat JD
    Clin Pharmacol Ther; 2019 Jul; 106(1):228-237. PubMed ID: 30673124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of transporters in the tissue-selective distribution and elimination of drugs: transporters in the liver, small intestine, brain and kidney.
    Kusuhara H; Sugiyama Y
    J Control Release; 2002 Jan; 78(1-3):43-54. PubMed ID: 11772448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor.
    Reese MJ; Savina PM; Generaux GT; Tracey H; Humphreys JE; Kanaoka E; Webster LO; Harmon KA; Clarke JD; Polli JW
    Drug Metab Dispos; 2013 Feb; 41(2):353-61. PubMed ID: 23132334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of hepatic drug transporter activity and expression by organochlorine pesticides.
    Bucher S; Le Vee M; Jouan E; Fardel O
    J Biochem Mol Toxicol; 2014 Mar; 28(3):119-28. PubMed ID: 24464585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The altered renal and hepatic expression of solute carrier transporters (SLCs) in type 1 diabetic mice.
    Xu C; Zhu L; Chan T; Lu X; Shen W; Gillies MC; Zhou F
    PLoS One; 2015; 10(3):e0120760. PubMed ID: 25789863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Membrane Transporters and Their Regulatory Mechanisms at the Brain and Retinal Barriers to Establish Therapies for Refractory Central Nervous System Diseases].
    Akanuma SI
    Yakugaku Zasshi; 2020; 140(10):1235-1242. PubMed ID: 32999202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT).
    Guo A; Marinaro W; Hu P; Sinko PJ
    Drug Metab Dispos; 2002 Apr; 30(4):457-63. PubMed ID: 11901101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.